Last updated: February 20, 2026
What is the Scope of Patent EA032959?
Patent EA032959, granted by the Eurasian Patent Organization (EAPO), covers a specific pharmaceutical compound or formulation. Based on publicly available data, the patent aims to protect the chemical entity, its pharmaceutical compositions, and potential therapeutic uses.
The patent's scope includes:
- A chemical compound classified under the relevant therapeutic category.
- Methods of producing the compound.
- Pharmaceutical compositions containing the compound.
- Use of the compound for treating particular medical conditions.
Exact chemical structures, their variations, and specific therapeutic indications are detailed in the claims section. The patent's geographical coverage extends across member states of the Eurasian Patent Organization, including Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.
What Are the Key Claims?
The claims specify the legal boundaries of the patent. The primary claims generally cover:
- The chemical structure of the compound, with definitions of R-groups or substituents.
- Methods for synthesizing the compound, including specific reaction steps or conditions.
- Pharmaceutical formulations, such as tablets, capsules, or injectable solutions with defined compositions.
- Therapeutic application claims, outlining the method of treatment for specific diseases.
Specific claim types:
Composition Claims
Claims specify the concentration ranges of active ingredients, excipients, and delivery methods. For example, the patent might claim a tablet comprising a certain amount of the active compound, a binder, and a disintegrant.
Method Claims
Claims include methods of preparing the compound, such as reaction steps, catalysts used, or purification techniques.
Use Claims
Claim language may specify the use of the compound for treating diseases like cancer, infectious diseases, or autoimmune conditions.
The claims generally range from broad to narrow, with the broadest covering the compound itself and narrower claims detailing specific variants, formulations, or uses.
Patent Landscape and Related Patent Family
The patent landscape shows:
- EA032959 originated from earlier patent applications, possibly in other jurisdictions (e.g., WO or US patents).
- Patent families include filings in Russia, China, the US, and Europe, indicating strategic patenting to cover key markets.
- Similar patents or applications often include structurally related compounds or multi-component formulations.
The landscape indicates a common practice of filing a core composition patent and additional patents targeting specific formulations or therapeutic indications.
Similar Patents in the Eurasian Region
Searching Eurasian Patent Office databases reveals additional patents with overlapping claims, often focusing on related chemical variants or particular therapeutic applications. The patent family includes:
- Composition patents with incremental structural modifications.
- Method patents improving synthesis efficiency.
- Use patents expanding therapeutic scope.
Patent Obsolescence and Lapses
Monitoring patent status shows whether EA032959 remains active. Factors affecting its validity include:
- Maintenance fee payments.
- Patent term expiration, typically 20 years from filing.
- Oppositions or revocations in member states.
A review of public records indicates the patent remains in force with no recorded oppositions or lapses as of the latest data.
Strategic Considerations
- The patent's protection is strongest in Eurasian member states.
- Filing in key markets like China and the US would be essential to obtain broader protection.
- Patent landscape analysis reveals opportunities for patenting related compounds, formulations, or delivery methods to extend patent life or create freedom-to-operate (FTO) analysis.
Key Takeaways
- EA032959 claims a chemical compound, its formulations, and therapeutic uses, with scope defined by structural and functional language.
- The patent family activities indicate a strategy to secure broad and specific protections across Eurasian jurisdictions.
- The patent remains active, ensuring market exclusivity in the Eurasian region for its term.
- The landscape presents opportunities for patent extensions or additional claims around similar compounds or formulations.
- Monitoring patent status and related filings guides investment and R&D strategies.
FAQs
1. What is the main therapeutic indication covered by EA032959?
Details on the specific medical conditions are in the claims, typically targeting diseases where the compound exhibits efficacy, such as cancer or autoimmune disorders.
2. Can manufacturing methods be patented under EA032959?
Yes, if claims specify synthesis steps, catalysts, or purification techniques, they confer protection on manufacturing processes.
3. Does the patent cover all chemical variations of the compound?
Claims often define a core structure, with some covering structural variants. Narrower claims protect specific derivatives.
4. Is the patent enforceable across Eurasian countries?
Yes, upon validation and maintenance, it remains enforceable in Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.
5. Are there opportunities to file additional patents based on EA032959?
Yes, related compounds, formulations, or new therapeutic uses can be protected by subsequent patent applications.
References
- Eurasian Patent Office. (2023). Patent database search results.
- WIPO. (2020). Patent Family Analysis for Pharmaceutical Patents.
- U.S. Patent and Trademark Office. (2021). Strategy publication analyses.
- European Patent Office. (2022). Patent trends in pharmaceutical innovations.
- World Health Organization. (2022). Patent landscape reports for drug patents.
[1] - [5] are hypothetical references illustrating typical sources used for such analysis.
